Xizhi, Taiwan

Shu Fu Lin

This inventor holds 1 USPTO granted patent. Top assignee: Development Center for Biotechnology. Active years: 2011.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shu Fu Lin. Retrieved from https://idiyas.com/inventor/shu-fu-lin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Shu Fu Lin

Introduction

Shu Fu Lin is a notable inventor based in Xizhi, Taiwan. He has made significant contributions to the field of biotechnology, particularly in the development of kinase inhibitors. His work focuses on creating compounds that can potentially treat serious diseases, including cancer.

Latest Patents

Shu Fu Lin holds a patent for "Indolinone compounds as kinase inhibitors." This patent includes indolinone compounds of specific formulas, wherein various components are defined. The patent also discloses methods for decreasing the activity of a protein kinase and for treating protein kinase-related diseases, such as cancer, using these compounds. He has 1 patent to his name.

Career Highlights

Shu Fu Lin is associated with the Development Center for Biotechnology, where he has been instrumental in advancing research and development in the field. His expertise in biotechnology and pharmacology has led to innovative solutions that address critical health issues.

Collaborations

He has collaborated with notable colleagues, including Jiann-Jyh Huang and Chao-Cheng Chiang, to further enhance the impact of his research and inventions.

Conclusion

Shu Fu Lin's contributions to biotechnology, particularly through his patent on indolinone compounds, highlight his role as an innovator in the field. His work continues to pave the way for advancements in treating diseases related to protein kinases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…